All data are based on the daily closing price as of May 23, 2024

Ildong Pharmaceutical Reports 3Q 2023 Business Performance

South Korea
i 249420.KO Mid and Small Cap 2000
Share this on

Ildong Pharmaceutical, a leading player in the pharmaceutical industry, has released its 3Q 2023 Interim Report on Business Performance. The report reveals a 3.0% decline in current quarter sales compared to the previous quarter, resulting in a cumulative sales decrease of 7.4% year-on-year.

Operating income, on the other hand, exhibits a positive trend with a 10.7% improvement from the preceding period. However, net income from continuing operations before income tax experienced a substantial decline, marking a significant shift in the company’s financial landscape.

It is important to note that these results are presented based on K-IFRS and are subject to potential adjustments following an external auditor review.

Share this on
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top